EUVIMEDEUVIMED entdecken
KommentarOpen Access

Cutaneous Lymphoma International Prognostic Index and Risk Stratification in Advanced Mycosis Fungoides and Sézary Syndrome

Gabriele Roccuzzo, Abraham Bashir, Felicity Evison, Sean Whittaker, Martine Bagot, Emmanuella Guenova, Evangelia Papadavid, Henry Miles Prince, Jose A Sanches, Denis R Miyashiro, Octavio Servitje, Christiane Querfeld und 44 weitere

JAMA Dermatology · 07.10.2026

DOI: 10.1001/jamadermatol.2026.3856 ↗

Kurz gefasst

Kommentar in der Zeitschrift JAMA Dermatology, online erschienen am 07.10.2026. Verfasst von Gabriele Roccuzzo und 55 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Risk stratification in advanced mycosis fungoides and Sézary syndrome (MF/SS) remains suboptimal given that current TNMB (tumor, node, metastasis, blood) staging has limited prognostic value for clinically relevant outcomes.

Objective

To determine whether the Cutaneous Lymphoma International Prognostic Index (CLIPI) may be used to predict progression-free survival (PFS) and best objective response (BOR) in patients with advanced MF/SS. Design, Setting, and Participants This international prospective cohort study included patients with stage IIB to IVB MF/SS from the PROCLIPI trial which ran from July 1, 2015, to May 1, 2025, across 46 referral centers. Median follow-up was 4.75 (95% CI, 4.04-5.13) years; eligible participants had complete data on CLIPI, PFS, and BOR. Data were analyzed from September 1 to December 1, 2025. Exposure CLIPI score at diagnosis, based on age (>60 years), elevated serum lactate dehydrogenase, N3 nodal status, and large-cell transformation in the skin. Patients were classified as having low (0 or 1 factor), intermediate (2 factors), or high risk (3 or 4 factors). Main Outcomes and Measures PFS (defined as diagnosis to disease progression or death) and BOR (complete response, partial response, stable disease, or progressive disease) during follow-up. Exploratory analyses evaluated treatment effects before progression using inverse probability weighting.

Results

Among 277 patients (median [IQR] age at diagnosis, 66 [23-89] years; 183 male individuals [65.7%]), 144 (52.0%) were classified as having low risk, 93 (33.6%) intermediate risk, and 40 (14.4%) high risk. They had a median PFS of 4.64 years (95% CI, 3.50-5.76), 2.72 years (95% CI, 1.81-4.56), and 0.89 years (95% CI, 0.65-1.14), respectively (log-rank P < .001). Patients in the intermediate-risk (hazard ratio [HR], 1.45; 95% CI, 1.01-2.08) and high-risk (HR, 3.84; 95% CI, 2.21-6.66) CLIPI groups displayed higher hazards of progression or death than those at low risk. Inclusion of CLIPI improved PFS discrimination over a model with baseline stage alone. Each 1-point increase in CLIPI was associated with approximately 38% lower odds of observing a better response during follow-up (odds ratio, 0.62; 95% CI, 0.43-0.89). Conclusions and Relevance In this international prospective cohort of patients with advanced MF/SS, CLIPI scores were associated with risk of disease progression and likelihood of response beyond clinical stage. These findings indicate that CLIPI may help to refine risk stratification and support its integration into clinical decision-making and future trial design.

Autor:innen und Institutionen

  • Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy.
  • Department of Dermatology, University Hospitals Birmingham NHS Foundation Trust & University of Birmingham, Birmingham, UK.
  • St Johns Institute of Dermatology, King's College London, London, UK.
  • Hôpital Saint Louis, Université Paris Cité, Paris, France.
  • Department of Dermatology, University Hospital Zurich and Faculty of Medicine, University of Zurich, Zurich, Switzerland.
  • University Department of Dermatology, University of Lausanne and Lausanne University Hospital, Lausanne, Switzerland.

Zitieren

APA

Roccuzzo, G., Bashir, A., Evison, F., Whittaker, S., Bagot, M., Guenova, E., Papadavid, E., Prince, H. M., Sanches, J. A., Miyashiro, D. R., Servitje, O., Querfeld, C., Akilov, O., Arumainathan, A., Bennett, L., Battistella, M., Bayne, M., Alberti Violetti, S., Fava, P., …, & Scarisbrick, J. (2026). Cutaneous Lymphoma International Prognostic Index and Risk Stratification in Advanced Mycosis Fungoides and Sézary Syndrome. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2026.3856

Vancouver

Roccuzzo G, Bashir A, Evison F, Whittaker S, Bagot M, Guenova E, et al. Cutaneous Lymphoma International Prognostic Index and Risk Stratification in Advanced Mycosis Fungoides and Sézary Syndrome. JAMA Dermatology. 2026. doi:10.1001/jamadermatol.2026.3856

BibTeX
@article{Roccuzzo2026,
  author = {Roccuzzo, Gabriele and Bashir, Abraham and Evison, Felicity and Whittaker, Sean and Bagot, Martine and Guenova, Emmanuella and Papadavid, Evangelia and Prince, Henry Miles and Sanches, Jose A and Miyashiro, Denis R and Servitje, Octavio and Querfeld, Christiane and Akilov, Oleg and Arumainathan, Arvind and Bennett, Luke and Battistella, Maxime and Bayne, Mike and Alberti Violetti, Silvia and Fava, Paolo and Iselin, Christoph and Beylot-Barry, Marie and Busschots, Anne Marie and Cowan, Richard and Dummer, Reinhard and Dunnill, Giles and Estrach, Teresa and Geskin, Larisa and Gru, Alejandro A and Guitart, Joan and Herrera, Melba C and Hodak, Emmilia and Horwitz, Steve and Jonak, Constanze and Klemke, Claus-Detlev and Knobler, Robert and Mckay, Pam and Marschalkó, Marta and Massone, Cesare and Matin, Rubeta N and Mitteldorf, Christina and Novoa, Robert and Ortiz-Romero, Pablo and Pimpinelli, Nicola and Pujol, Ramon M and Rieger, Kerri E and Stadler, Rudolf and Trautinger, Franz and Latzka, Johanna and Vermeer, Maarten and Wachsmuth, Rachel and Weatherhead, Sophie and Wehkamp, Ulrike and Wobser, Marion and Quaglino, Pietro and Kim, Youn H and Scarisbrick, Julia},
  title = {Cutaneous Lymphoma International Prognostic Index and Risk Stratification in Advanced Mycosis Fungoides and Sézary Syndrome},
  journal = {JAMA Dermatology},
  year = {2026},
  doi = {10.1001/jamadermatol.2026.3856}
}
Kostenlos starten →